Cholinesterase inhibitors and cardiovascular disease: a survey of old age psychiatrists' practice

Malone, Darren M.; Lindesay, James
May 2007
Age & Ageing;May2007, Vol. 36 Issue 3, p331
Academic Journal
The article focuses on a study on the use of cholinesterase inhibitor (ChEI) drug donepezil in the treatment of Alzheimer's disease (AD) in England. Syncope is said to be a common side effect of the drug. It cites the effects of the prescription of ChEIs without proper care and supervision to patients. It stresses the importance of developing consensus guidelines as to what is the best practice in monitoring patients with cardiovascular comorbidities who are prescribed with ChEI.


Related Articles

  • Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. O L Lopez // Journal of Neurology, Neurosurgery & Psychiatry;Jun2009, Vol. 80 Issue 6, p600 

    BACKGROUND: Patients using cholinesterase inhibitors (ChEIs) have a delay in nursing home (NH) admission compared with those who were not using the medication. There are no long-term studies of the effects of memantine in combination with ChEIs use in Alzheimer disease (AD). This study was...

  • Long-Term Efficacy and Toxicity of Cholinesterase Inhibitors in the Treatment of Alzheimer Disease. Hogan, David B. // Canadian Journal of Psychiatry;Dec2014, Vol. 59 Issue 12, p618 

    Though the symptoms of Alzheimer disease go on for years, the phase 3 trials of the cholinesterase inhibitors (ChEls), the current mainstay of symptomatic pharmacotherapy for this condition, were typically of only 3- to 6-months' duration. We have limited data on long-term (that is, a year or...

  • Fighting Alzheimer's. Sederstrom, Jill // Drug Topics;Nov2011, Vol. 155 Issue 11, p36 

    The article reports on the availability of disease-modifying drugs that could alter how Alzheimer's disease is attacked and might offer pharmacists more therapeutic alternatives in the U.S. It mentions that there are medications that seek to slow the progression of the disease and reduce...

  • Treatment of Alzheimer's Disease. Mayeux, Richard; Sano, Mary // New England Journal of Medicine;11/25/99, Vol. 341 Issue 22, p1670 

    Focuses on drugs approved by the United States Food and Drug Administration (FDA) for the treatment of Alzheimer's disease. Detailed review of drugs given clinical trials for at least six months; Statistics on the incidence of the disease worldwide; Criteria for the diagnosis of Alzheimer's...

  • Review: cholinesterase inhibitors have a modest effect on neuropsychiatric and functional outcomes in Alzheimer's disease. Trinh, N. H.; Hoblyn, J.; Mohanty, S.; Yaffe, K. // Evidence Based Mental Health;Aug2003, Vol. 6 Issue 3, p94 

    Cholinesterase inhibitors appear to have a modest effect on neuropsychiatric and functional outcomes in Alzheimer's disease (AD). It is uncertain whether these benefits affect long term outcomes such as quality of life, institutionalisation and caregiver burden. Controversy remains about the...

  • Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease? Giacobini, E. // CNS Drugs;2001, Vol. 15 Issue 2, p85 

    During the last decade, a systematic effort to develop a pharmacological treatment for Alzheimer disease (AD) has resulted in drugs being registered for the first time in the US and Europe for this specific indication. The 3 agents registered are cholinesterase inhibitors (ChEIs). The major...

  • Beyond Tacrine: Recently Developed Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease. Unni, L.K. // CNS Drugs;1998, Vol. 10 Issue 6, p447 

    Alzheimer's disease still remains a diagnosis of exclusion. Until treatment strategies aimed at targeting its underlying aetiology become available, a cholinergic approach appears to be the most promising treatment for improving cognition in this devastating disease. Research to date suggests...

  • Cholinergic nicotinic systems in Alzheimer's disease: prospects for pharmacological intervention. Vesey, R.; Birrell, J.M.; Bolton, C.; Chipperfield, R.S.; Blackwell, A.D.; Dening, T.R.; Sahakian, B.J.; Vesey, Robyn; Birrell, Jennifer M; Bolton, Clare; Chipperfield, Ruth S; Blackwell, Andrew D; Dening, Tom R; Sahakian, Barbara J // CNS Drugs;2002, Vol. 16 Issue 7, p485 

    Within the last few years, research into the cause and progression of Alzheimer's disease has made significant advances. Although there is still no preventative treatment or cure for this neurodegenerative illness, the development of drugs that may alleviate some of the cognitive symptoms...

  • Clinical Pharmacokinetics and Pharmacodynamics of Cholinesterase Inhibitors. Jann, M.W.; Shirley, K.L.; Small, G.W. // Clinical Pharmacokinetics;2002, Vol. 41 Issue 10, p719 

    Cholinesterase inhibitors are the ‘first-line’ agents in the treatment of Alzheimer's disease. This article presents the latest information on their pharmacokinetic properties and pharmacodynamic activity. Tacrine was the first cholinesterase inhibitor approved by regulatory...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics